At TechCrunch's sold-out StrictlyVC event in San Francisco on Thursday night, we covered a lot of ground in a short time, ...
First-in-Class enVVe system to be evaluated in TAVVE U.S. Pivotal TrialClinical site activation and patient enrollment expected to commence later this yearLarge unmet clinical need for approximately 3 ...
Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). Such investors are ...
Tragic circumstances are at least generally natural or accidental.
4d
Replit's CEO says it's dumb to study computer science thinking you can make a 'boatload' at Google
Amjad Masad said that young people who are not deeply interested in computer science should not study it.
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced multiple presentations at the 2026 American ...
Strip away the theatre — including the surreal moment when Israel’s Foreign Ministry summoned Spain’s chargé d’affaires over an Andalusian “Burning of Judas” effigy of Netanyahu stuffed with gunpowder ...
When McLaren announced earlier this month that it had prised GianPiero Lambiase away from Red Bull Racing, our immediate read ...
Saudi Arabia made their coaching change official Thursday by firing Hervé Renard and replacing him with Georgios Donis less ...
Health Secretary Robert F. Kennedy Jr. told a Senate hearing on Wednesday that he had nothing to do with the U.S. FDA's ...
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...
At a Senate hearing, U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said on Wednesday that he "had nothing to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results